Detall de la convocatòria


Objectiu de la convocatòria
The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries.
Característiques principals
The EFSD/Novo Nordisk Partnership for Diabetes Research in Europe Programme will accept applications from all fields of diabetes research and including both basic and clinical research.
Lloc de presentació
El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
Marta López: [email protected] Ext.: 1576
Carol Barnwell: [email protected] Ext.: 1670
Convocatòria (URL)
Applications for an EFSD/Novo Nordisk grant are invited from single non-profit institutions or groups of such institutions from Europe and associated countries. The principal investigator and any co-investigators must be normally employed at a non-profit institution and the study must be performed at their place of work.
Up to Euro 100,000 for basic research projects and Euro 400,000 for clinical research projects.The definition of clinical research is a study performed in human individuals and where there is a focus on a clinically relevant and diabetes-related outcome.
Applications with a funding requirement larger than that specified above may be considered.
The duration of each award will depend upon the needs of the project and as justified in the application.


EFSD and Novo Nordisk A_S Programme for Diabetes Research in Europe _ EFSD.pdf